Ron Shinkman

Los Angeles

Writer and Editor at Freelance

Editor and Reporter at Health Payer Specialist

Editor and Reporter at Financial Times

Articles

FDA Watch: CDRH Budget May Not See Steep Cuts in FY 2026

2 weeks ago | g2intelligence.com | Ron Shinkman

A leaked budget document for the next fiscal year suggested non-user fee funding may be up slightly compared to recent years.
Dx Deals: Quest Diagnostics M&A Centers on Precision-Focused Approach

1 month ago | g2intelligence.com | Ron Shinkman

Recent inroads into testing of water for dialysis equipment illustrates Quest’s expanded scope with deals
Diagnostics Pipeline: Savara Introduces Blood Test to Detect aPAP, a Rare Lung Disorder

1 month ago | g2intelligence.com | Ron Shinkman

Savara’s ClearPath assay needs just a few drops of blood to test for aPAP, a condition that can be difficult and invasive to diagnose
FDA Watch: DOGE Changes at FDA Upend Approval Processes, Observers Say

2 months ago | g2intelligence.com | Ron Shinkman

Pre-submission and Q-Submission meetings apparently have been halted, for now
Further Details to Note about Updated Clinical Lab Director Qualifications

2 months ago | g2intelligence.com | Ron Shinkman

by | Mar 20, 2025 | CLIA-lca, CLIA-nir, CMS-lca, CMS-nir, Compliance-lca, Employment-lca, Lab Industry Advisor Put into place late last year, the new rules place more emphasis on formal and continuing education requirements Put into place late last year, the new rules place more emphasis on formal and continuing education requirements Subscribe to View Start a Free Trial for immediate access to this article...
Diagnostics Pipeline: Roche’s New Cobas Liat Panel Can Test for Multiple STIs Simultaneously

2 months ago | g2intelligence.com | Ron Shinkman

The PCR-driven test provides results in about 20 minutes in non-laboratory settings
Dx Deals: BD Laboratory Business Is Up for Grabs in Bold Move

Feb 28, 2025 | g2intelligence.com | Ron Shinkman

Becton Dickinson divisions responsible for $3.4 billion in annual revenue are on the block
MeMed Sepsis Test Gains Breakthrough Device Designation

Jan 31, 2025 | g2intelligence.com | Ron Shinkman

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to a new test from Israeli firm MeMed that can diagnose a suspected case of sepsis within minutes.1 Sepsis is the body’s severe inflammatory reaction to an infection. This inflammation can lead to clots in blood vessels, hampering blood flow to the body’s internal organs.
Labcorp, Quest, and ARUP Develop Bird Flu Tests with CDC Help

Jan 28, 2025 | g2intelligence.com | Ron Shinkman

Three laboratories have quickly developed and released tests for H5N1 bird flu in conjunction with the Centers for Disease Control and Prevention (CDC). These partnerships reflect a recent trend of increased public-private partnerships in the laboratory industry to boost pandemic preparedness. The tests were developed and released by Labcorp, Quest Diagnostics, and ARUP Laboratories, according to the CDC and statements issued by the companies in recent weeks.
Could Health Coaching Be a New Opportunity for Labs?

Jan 24, 2025 | g2intelligence.com | Ron Shinkman

One of the largest laboratory companies in the United States has launched a new business focused on an unusual path: health coaching of individual patients. Quest Diagnostics has begun offering health coaching packages beginning at $225 apiece through its Pack Health subsidiary.